Pharmacologic inhibition of Wnt ligand signaling supports anti-PD-1 efficacy by reversing the recruitment of G-MDSCs in an autochthonous model of melanoma and non-small-cell lung cancer (NSCLC) (76). This evidence concerns the gene PDCD1 and melanoma.